Phase I clinical trial of bortezomib in
β
David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F
π
Article
π
2006
π
John Wiley and Sons
π
English
β 114 KB
π 2 views
## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and doseβlimiting toxicities (DLTs) of bortezomib in combi